Free Trial
NYSE:JNJ

Johnson & Johnson Q3 2025 Earnings Report

Johnson & Johnson logo
$177.49 -0.57 (-0.32%)
Closing price 09/15/2025 03:59 PM Eastern
Extended Trading
$177.50 +0.01 (+0.01%)
As of 09/15/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson EPS Results

Actual EPS
N/A
Consensus EPS
$2.78
Beat/Miss
N/A
One Year Ago EPS
N/A

Johnson & Johnson Revenue Results

Actual Revenue
N/A
Expected Revenue
$23.73 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Johnson & Johnson Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Tuesday, October 14, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Johnson & Johnson Earnings Headlines

Reagan’s former tech advisor sharing bombshell announcement
George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.tc pixel
Johnson & Johnson (NYSE:JNJ) Stock Rating Upgraded by Wall Street Zen
See More Johnson & Johnson Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Johnson & Johnson? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Johnson & Johnson and other key companies, straight to your email.

About Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) (NYSE: JNJ) is a diversified global healthcare company that develops, manufactures and sells a broad range of products in three primary business segments: Pharmaceuticals, Medical Devices and Consumer Health. Founded in 1886 by brothers Robert Wood Johnson, James Wood Johnson and Edward Mead Johnson, the company pioneered sterile surgical dressings and has since expanded into prescription medicines, diagnostics and advanced medical technologies, as well as over-the-counter healthcare products.

In its Pharmaceuticals segment, Johnson & Johnson researches and commercializes treatments in areas such as immunology, oncology, neuroscience and infectious diseases. The Medical Devices segment offers a wide array of surgical systems, orthopaedic devices, cardiovascular care solutions and vision care products. Within Consumer Health, the company markets well-known brands in skin care, baby care, wound care, oral hygiene and women’s health. Together, these divisions serve healthcare professionals, consumers and patients around the world.

Headquartered in New Brunswick, New Jersey, Johnson & Johnson operates in more than 60 countries and sells products in virtually every market worldwide. The company maintains research and development facilities across North America, Europe and Asia, supporting collaborations with academic institutions and biotechnology firms. As of 2022, Johnson & Johnson is led by Chairman and Chief Executive Officer Joaquin Duato, under whose leadership the company continues to pursue innovation and sustainable growth within the global healthcare industry.

View Johnson & Johnson Profile

More Earnings Resources from MarketBeat